SeraCare Life Sciences has launched what it claims to be the first commercially available anti-dengue mixed titer performance panel. This addition to the company’s line of infectious disease panels responds to growing demand for accurate testing for dengue virus, which infects an estimated 50 to 100 million people annually, according to the World Health Organization.
The performance panel is designed to help blood-donor collection facilities, diagnostics manufacturers and clinical laboratories evaluate and troubleshoot their anti-dengue virus assays. It is derived from undiluted, unpreserved human plasma specimens, with 21 members representing a wide range of reactivity for anti-dengue IgM and IgG antibodies, from negative to strongly positive. Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).
Phone: 07 3386 7999
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
Grace Bio-Labs protein microarray tools
Grace Bio-Labs' microarray substrates provide high binding capacity and enable high assay...
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
